Skip to main content
SpringerLink
Log in

Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

The association between hepatitis B and concomitant diseases, such as fatty liver, T2DM, MetS, and Hp infection, remains unclear.

Aim

The present study was to illustrate the association and explore the co-contribution on abnormal transaminase and progression of liver stiffness.

Methods

A total of 95,998 participants underwent HBsAg screening in West China Hospital from 2014 to 2017. Multivariable logistic regression was used to determine the adjusted odds ratios.

Results

The prevalence of HBsAg-positive rate was 8.30% of our included study population. HBsAg positive was associated with negative risk of fatty liver (odds ratio [OR] 0.71, 95% confidence interval [CI] 0.65–0.78, p < 0.001) and MetS (OR 0.74, 95% CI 0.67–0.84, p < 0.001), and with positive risk of Hp infection (OR 1.09, 95% CI 1.02–1.17, p = 0.012) and T2DM (OR 1.18, 95% CI 1.01–1.40, p = 0.043). Besides, HBsAg-positive patients with T2DM had higher risk of elevated ALT (OR 2.09, 95% CI 1.69–2.83, p < 0.001 vs OR 1.59, 95% CI 1.51–1.68, p < 0.001), AST (OR 2.69, 95% CI 1.98–3.65, p < 0.001 vs OR 1.89, 95% CI 1.76–2.02, p < 0.001) than HBV alone. In addition to HBV, T2DM also can increase the risk of liver fibrosis (OR 3.23, 95% CI 1.35–7.71, p = 0.008) and cirrhosis (OR 4.31, 95% CI 1.41–13.20, p = 0.010).

Conclusion

Hepatitis B patients have a lower risk of fatty liver and MetS, and a higher risk of T2DM and Hp infection. Besides, T2DM might be possibly associated with abnormal liver transaminase and fibrosis progression in HBsAg-positive patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

CHB:

Chronic hepatitis B

HBV:

Hepatitis B virus

HCC:

Hepatocellular carcinoma

NAFLD:

Nonalcoholic fatty liver

HBsAg:

Hepatitis B surface antigen

T2DM:

Type 2 diabetes mellitus

NASH:

Nonalcoholic steatohepatitis

MetS:

Metabolic syndrome

Anti-HCV:

Anti-hepatitis C virus

CAP:

Controlled attenuation parameter

EASL:

European Association for the Study of the Liver

TSH:

Thyroid-stimulating hormone

FT4:

Free thyroxine

HDL:

High-density lipoprotein

aOR:

Adjusted odds ratio

SD:

Standard deviation

BMI:

Body mass index

References

  1. Seto WK, Lo YR, Pawlotsky JM et al. Chronic hepatitis B virus infection. Lancet 2018;392:2313–2324.

    Article  PubMed  Google Scholar 

  2. Yuen MF, Chen DS, Dusheiko GM et al. Hepatitis B virus infection. Nature Reviews Disease Primers 2018;4:18035.

    Article  PubMed  Google Scholar 

  3. Pais R, Rusu E, Zilisteanu D et al. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. European Journal of Internal Medicine 2015;26:30–36.

    Article  CAS  PubMed  Google Scholar 

  4. Wang MM, Wang GS, Shen F et al. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Digestive Diseases and Sciences 2014;59:2571–2579.

    Article  CAS  PubMed  Google Scholar 

  5. Leandro G, Mangia A, Hui J et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130:1636–1642.

    Article  PubMed  Google Scholar 

  6. Peng D, Han Y, Ding H et al. Hepatic steatosis in chronic hepatitis B patients is associated with metabolic factors more than viral factors. Journal of Gastroenterology and Hepatology 2008;23:1082–1088.

    Article  CAS  PubMed  Google Scholar 

  7. Wong VW, Wong GL, Chu WC et al. Hepatitis B virus infection and fatty liver in the general population. J Hepatol 2012;56:533–540.

    Article  PubMed  Google Scholar 

  8. Jan CF, Chen CJ, Chiu YH et al. A population-based study investigating the association between metabolic syndrome and hepatitis B/C infection (Keelung Community-based Integrated Screening study No. 10). Int J Obes (Lond) 2006;30:794–799.

    Article  PubMed  Google Scholar 

  9. Yun JW, Cho YK, Park JH et al. Hepatic steatosis and fibrosis in young men with treatment-naïve chronic hepatitis B. Liver International : Official Journal of the International Association for the Study of the Liver 2009;29:878–883.

    Article  CAS  PubMed  Google Scholar 

  10. Li Y, Teng D, Shi X et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ 2020;369:m997.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Lu J, Hou X, Tu H et al. Chronic hepatitis B virus infection status is more prevalent in patients with type 2 diabetes. Journal of Diabetes Investigation 2017;8:619–625.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Han B, Liu W, Yang S et al. Association between self-monitoring of blood glucose and hepatitis B virus infection among people with diabetes mellitus: a cross-sectional study in Gansu Province, China. BMJ Open 2021;11:e048463.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Schillie SF, Xing J, Murphy TV et al. Prevalence of hepatitis B virus infection among persons with diagnosed diabetes mellitus in the United States, 1999–2010. Journal of Viral Hepatitis 2012;19:674–676.

    Article  CAS  PubMed  Google Scholar 

  14. Reilly ML, Schillie SF, Smith E et al. Increased risk of acute hepatitis B among adults with diagnosed diabetes mellitus. Journal of Diabetes Science and Technology 2012;6:858–866.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Li-Ng M, Tropp S, Danoff A et al. Association between chronic hepatitis B virus infection and diabetes among Asian Americans and Pacific Islanders. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2007;39:549–556.

    Article  CAS  PubMed  Google Scholar 

  16. Whalen MB, Massidda O. Helicobacter pylori: enemy, commensal or, sometimes, friend? Journal of Infection in Developing Countries 2015;9:674–678.

    Article  CAS  PubMed  Google Scholar 

  17. Tan HJ, Goh KL. Extragastrointestinal manifestations of Helicobacter pylori infection: facts or myth? A critical review. Journal of Digestive Diseases 2012;13:342–349.

    Article  CAS  PubMed  Google Scholar 

  18. Waluga M, Kukla M, Żorniak M et al. From the stomach to other organs: Helicobacter pylori and the liver. World Journal of Hepatology 2015;7:2136–2146.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Fan XG, Zou YY, Wu AH et al. Seroprevalence of Helicobacter pylori infection in patients with hepatitis B. British Journal of Biomedical Science 1998;55:176–178.

    CAS  PubMed  Google Scholar 

  20. Ponzetto A, Pellicano R, Leone N et al. Helicobacter pylori seroprevalence in cirrhotic patients with hepatitis B virus infection. The Netherlands Journal of Medicine 2000;56:206–210.

    Article  CAS  PubMed  Google Scholar 

  21. Nandakumar R, Naik AS, Pandit B et al. Effect of Helicobacter pylori eradication on serum ammonia levels in patients with chronic liver disease. Indian Journal of Gastroenterology: Official Journal of the Indian Society of Gastroenterology 2003;22:221–223.

    CAS  PubMed  Google Scholar 

  22. Abu Al-Soud W, Stenram U, Ljungh A et al. DNA of Helicobacter spp. and common gut bacteria in primary liver carcinoma. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2008;40:126–131.

    Article  CAS  PubMed  Google Scholar 

  23. Wang J, Chen RC, Zheng YX et al. Helicobacter pylori infection may increase the risk of progression of chronic hepatitis B disease among the Chinese population: a meta-analysis. Int J Infect Dis 2016;50:30–37.

    Article  PubMed  Google Scholar 

  24. Luo W, Wu S, Chen H et al. Thyroid dysfunction is associated with the loss of hepatitis B surface antigen in patients with chronic hepatitis B undergoing treatment with α-interferon. The Journal of International Medical Research 2021;49:3000605211025139.

    Article  CAS  PubMed  Google Scholar 

  25. Yeo YH, Ho HJ, Yang HI et al. Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. Gastroenterology 2019;156:635-646.e639.

    Article  CAS  PubMed  Google Scholar 

  26. McPherson S, Hardy T, Henderson E et al. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. Journal of Hepatology 2015;62:1148–1155.

    Article  PubMed  Google Scholar 

  27. Ekstedt M, Hagström H, Nasr P et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology (Baltimore, Md) 2015;61:1547–1554.

    Article  CAS  PubMed  Google Scholar 

  28. Wang C, Wang X, Gong G et al. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. International Journal of Cancer 2012;130:1639–1648.

    Article  CAS  PubMed  Google Scholar 

  29. Campbell PT, Newton CC, Freedman ND et al. Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for U.S. Adults. Cancer Research 2016;76:6076–6083.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460–468.

    Article  PubMed  Google Scholar 

  31. Wong GL, Wong VW, Choi PC et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut 2009;58:111–117.

    Article  PubMed  Google Scholar 

  32. Lesmana LA, Lesmana CR, Pakasi LS et al. Prevalence of hepatic steatosis in chronic hepatitis B patients and its association with disease severity. Acta Med Indones 2012;44:35–39.

    PubMed  Google Scholar 

  33. Shi JP, Fan JG, Wu R et al. Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. J Gastroenterol Hepatol 2008;23:1419–1425.

    Article  PubMed  Google Scholar 

  34. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet (London, England). 2004;363:157–163.

  35. Saadeh S, Younossi ZM, Remer EM et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745–750.

    Article  PubMed  Google Scholar 

  36. Seto WK, Hui RWH, Mak LY et al. Association Between Hepatic Steatosis, Measured by Controlled Attenuation Parameter, and Fibrosis Burden in Chronic Hepatitis B. Clin Gastroenterol Hepatol 2018;16:575-583.e572.

    Article  PubMed  Google Scholar 

  37. Karlas T, Petroff D, Sasso M et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. J Hepatol 2017;66:1022–1030.

    Article  PubMed  Google Scholar 

  38. Dietrich CF, Bamber J, Berzigotti A et al. EFSUMB Guidelines and Recommendations on the Clinical Use of Liver Ultrasound Elastography, Update 2017 (Long Version). Ultraschall Med 2017;38:e16–e47.

    Article  PubMed  Google Scholar 

  39. EASL-ALEH Clinical Practice Guidelines. Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015;63:237–264.

    Article  Google Scholar 

  40. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol 2017;67:862–873.

    Article  PubMed  Google Scholar 

  41. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640–1645.

    Article  CAS  PubMed  Google Scholar 

  42. Executive summary: Standards of medical care in diabetes—2014. Diabetes Care. 2014;37:S5–13.

  43. Klein PD, Malaty HM, Martin RF et al. Noninvasive detection of Helicobacter pylori infection in clinical practice: the 13C urea breath test. Am J Gastroenterol 1996;91:690–694.

    CAS  PubMed  Google Scholar 

  44. Cooper DS, Biondi B. Subclinical thyroid disease. Lancet 2012;379:1142–1154.

    Article  PubMed  Google Scholar 

  45. Joo EJ, Chang Y, Yeom JS et al. Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study. Hepatology 2017;65:828–835.

    Article  CAS  PubMed  Google Scholar 

  46. Zhong GC, Wu YL, Hao FB et al. Current but not past hepatitis B virus infection is associated with a decreased risk of nonalcoholic fatty liver disease in the Chinese population: A case-control study with propensity score analysis. J Viral Hepat 2018;25:842–852.

    Article  CAS  PubMed  Google Scholar 

  47. Jiang W, Liu CH, Wu D et al. Abnormal transaminase and lipid profiles in coexisting diseases in patients with fatty liver: a population study in Sichuan. Bioscience Reports 2021. https://doi.org/10.1042/BSR20211769.

  48. Suliman I, Abdelgelil N, Kassamali F et al. The Effects of Hepatic Steatosis on the Natural History of HBV Infection. Clin Liver Dis 2019;23:433–450.

    Article  PubMed  Google Scholar 

  49. Lee JG, Lee S, Kim YJ et al. Association of chronic viral hepatitis B with insulin resistance. World J Gastroenterol 2012;18:6120–6126.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Wang CC, Cheng PN, Kao JH. Systematic review: chronic viral hepatitis and metabolic derangement. Aliment Pharmacol Ther 2020;51:216–230.

    Article  PubMed  Google Scholar 

  51. Wang CC, Hsu CS, Liu CJ et al. Association of chronic hepatitis B virus infection with insulin resistance and hepatic steatosis. Journal of Gastroenterology and Hepatology 2008;23:779–782.

    Article  PubMed  Google Scholar 

  52. Huang ZS, Huang TS, Wu TH et al. Asymptomatic chronic hepatitis B virus infection does not increase the risk of diabetes mellitus: a ten-year observation. J Gastroenterol Hepatol 2010;25:1420–1425.

    Article  PubMed  Google Scholar 

  53. Mohamed AA, Elshimy AA, El Sadik AO et al. Association between Severity of Liver Disease, Frequency of Helicobacter pylori Infection, and Degree of Gastric Lesion in Egyptian Patients with Hepatitis B Virus Infection. Am J Trop Med Hyg 2018;98:221–226.

    Article  PubMed  Google Scholar 

  54. Huang J, Cui J. Evaluation of Helicobacter pylori Infection in Patients with Chronic Hepatic Disease. Chin Med J (Engl) 2017;130:149–154.

    CAS  PubMed  Google Scholar 

  55. Wang MY, Yue JY, Zhang YX et al. Helicobacter pylori infection in asymptomatic HBV carriers, alcohol users and normal adult population in Shandong Province, China. Clinics and Research in Hepatology and Gastroenterology 2011;35:560–562.

    Article  PubMed  Google Scholar 

  56. Zheng RD, Chen JN, Zhuang QY et al. Clinical and virological characteristics of chronic hepatitis B patients with hepatic steatosis. Int J Med Sci 2013;10:641–646.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol 2011;26:1361–1367.

    PubMed  Google Scholar 

  58. Hsieh PS, Hsieh YJ. Impact of liver diseases on the development of type 2 diabetes mellitus. World Journal of Gastroenterology 2011;17:5240–5245.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Holstein A, Hinze S, Thiessen E et al. Clinical implications of hepatogenous diabetes in liver cirrhosis. Journal of Gastroenterology and Hepatology 2002;17:677–681.

    Article  PubMed  Google Scholar 

  60. Lee YB, Ha Y, Chon YE et al. Association between hepatic steatosis and the development of hepatocellular carcinoma in patients with chronic hepatitis B. Clin Mol Hepatol 2019;25:52–64.

    Article  PubMed  Google Scholar 

  61. Pang Y, Kartsonaki C, Turnbull I et al. Diabetes, Plasma Glucose, and Incidence of Fatty Liver, Cirrhosis, and Liver Cancer: A Prospective Study of 0.5 Million People. Hepatology 2018;68:1308–1318.

    Article  CAS  PubMed  Google Scholar 

  62. Ahmadieh H, Azar ST. Liver disease and diabetes: association, pathophysiology, and management. Diabetes Research and Clinical Practice 2014;104:53–62.

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This work was supported by 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (No. ZYGD20009), Post-Doctor Research Project of West China Hospital of Sichuan University (No. 2020HXBH079), Science and Technological Supports Project of Sichuan Province, China (No. 2021YFS0169), Science and Technological Supports Project of Sichuan Province, China (No. 2022YFS0338), and National Natural Science Foundation of China (No. 81900512).

Author information

Authors and Affiliations

  1. Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, China

    Chang-Hai Liu, Wei Jiang, Dong-Bo Wu, Qing-Min Zeng & Hong Tang

  2. Division of Infectious Diseases, State Key Laboratory of Biotherapy and Center of Infectious Disease, West China Hospital, Sichuan University, No. 37 Guoxue Alley, Chengdu, 610041, Sichuan, China

    Chang-Hai Liu, Wei Jiang, Dong-Bo Wu, Qing-Min Zeng & Hong Tang

  3. Health Management Center, West China Hospital of Sichuan University, Chengdu, China

    You-Juan Wang

Authors
  1. Chang-Hai Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Wei Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dong-Bo Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Qing-Min Zeng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. You-Juan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hong Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hong Tang.

Ethics declarations

Conflict of interest

The authors declare no potential conflicts (financial, professional, or personal) relevant to the manuscript.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, CH., Jiang, W., Wu, DB. et al. Concomitant Diseases and Co-contribution on Progression of Liver Stiffness in Patients with Hepatitis B Virus Infection. Dig Dis Sci 68, 1605–1614 (2023). https://doi.org/10.1007/s10620-022-07695-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-022-07695-2

Keywords

Search

Navigation